Akinyemi Oni-Orisan, PharmD, PhD

Title(s)Associate Professor, Clinical Pharmacy
SchoolSchool of Pharmacy
Address490 Illinois Street, #33N
San Francisco CA 94158
Phone415-502-7551
ORCID ORCID Icon0000-0002-5897-5543 Additional info
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of Michigan, Ann ArborBS12/2006Biology
    University of Michigan, Ann ArborPharmD05/2010Pharmacy
    University of North Carolina, Chapel HillPhD08/2015Pharmacotherapy and Experimental Therapeutics
    University of California, San FranciscoFellowship09/2017Clinical Pharmacology
    University of California, San Francisco06/2022Diversity, Equity, and Inclusion Champion Training

    Collapse Overview 
    Collapse Overview
    The long-term research goal of Dr. Oni-Orisan’s lab is to improve pharmacological regimens for the prevention and treatment of cardiovascular disease in diverse populations through precision medicine. To accomplish this objective, his group combines computational approaches in pharmacogenomics and pharmacoepidemiology using electronic health record-linked biobanks. His lab is currently funded to investigate genetic determinants of efficacy and safety for statin therapy in diverse populations.

    Dr. Oni-Orisan teaches and mentors pharmacy students in the Discovery Projects research program including leading the inaugural Health Disparities Discovery Group.

    Dr. Oni-Orisan serves as Diversity Leader for the Department of Clinical Pharmacy to champion diversity, equity and inclusion (DEI) efforts in the department.

    Collapse Research 
    Collapse Research Activities and Funding
    Development of a precision medicine tool to predict dysglycemic effects of statin treatment Objective: identify a set of candidate variants/genes/pathways associated with new-onset diabetes susceptibility in statin users
    UCSF/Marcus Precision - Transformative Integrated Research Apr 1, 2023 - Mar 31, 2024
    Role: Multiple Principal Investigator
    Optimization of statin regimens for atherosclerotic cardiovascular disease prevention using polygenic risk scores and real-world evidence
    NIH/NHLBI R56HL161518Sep 1, 2022 - Aug 31, 2023
    Role: Prinicpal Investigator
    The Impact of CYP2D6 Variation on Risperidone-related Side Effects in a Nigeria Pediatric Population Using the Child and Adolescent Mental Health Service Center of the Federal Neuro-Psychiatric Hospital, Yaba, Lagos, Nigeria
    Pharmacogenomics Global Research Network Jul 1, 2022 - Jun 30, 2023
    Role: Co-Principal Investigator
    Characterization of response to lipid-modifying regimens for atherosclerotic cardiovascular disease using electronic health records
    NIH K01HL143109Jul 15, 2018 - Jun 30, 2023
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Academic Senate

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. X chromosome dosage drives statin-induced dysglycemia and mitochondrial dysfunction. Nat Commun. 2024 Jul 02; 15(1):5571. Zhang P, Munier JJ, Wiese CB, Vergnes L, Link JC, Abbasi F, Ronquillo E, Scheker K, Muñoz A, Kuang YL, Theusch E, Lu M, Sanchez G, Oni-Orisan A, Iribarren C, McPhaul MJ, Nomura DK, Knowles JW, Krauss RM, Medina MW, Reue K. PMID: 38956041; PMCID: PMC11219728.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimalsCells
    2. Preferences and Perspectives of Black Male Barbershop Patrons on Receiving Health Care in Nontraditional Settings. Health Equity. 2023; 7(1):835-842. Chong S, Huynh B, Wong S, Woldeyesus T, Faulks M, El-Amin K, Thibeaux J, Lewis J, Harlin R, Carter M, Shatara R, Zhou C, Oni-Orisan A. PMID: 38145054; PMCID: PMC10739686.
      View in: PubMed   Mentions:
    3. SLCO1B1 functional variants and statin-induced myopathy in people with recent genealogical ancestors from Africa: a population-based real-world study. medRxiv. 2023 Dec 03. Yee SW, Haldar T, Kvale M, Yang J, Douglas MP, Oni-Orisan A. PMID: 38076949; PMCID: PMC10705643.
      View in: PubMed   Mentions:
    4. Low- and High-Density Lipoprotein Cholesterol and Dementia Risk Over 17 Years of Follow-up Among Members of a Large Health Care Plan. Neurology. 2023 Nov 21; 101(21):e2172-e2184. Ferguson EL, Zimmerman SC, Jiang C, Choi M, Swinnerton K, Choudhary V, Meyers TJ, Hoffmann TJ, Gilsanz P, Oni-Orisan A, Whitmer RA, Whitmer RA, Risch N, Krauss RM, Schaefer CA, Glymour MM. PMID: 37793911; PMCID: PMC10663022.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    5. Metformin Cessation and Dementia Incidence. JAMA Netw Open. 2023 10 02; 6(10):e2339723. Zimmerman SC, Ferguson EL, Choudhary V, Ranatunga DK, Oni-Orisan A, Hayes-Larson E, Duarte Folle A, Mayeda ER, Whitmer RA, Whitmer RA, Gilsanz P, Power MC, Schaefer C, Glymour MM, Ackley SF. PMID: 37878309; PMCID: PMC10600586.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    6. An Introductory Tutorial on Cardiovascular Pharmacogenetics for Healthcare Providers. Clin Pharmacol Ther. 2023 08; 114(2):275-287. Oni-Orisan A, Tuteja S, Hoffecker G, Smith DM, Castrichini M, Crews KR, Murphy WA, Nguyen NHK, Huang Y, Lteif C, Friede KA, Tantisira K, Aminkeng F, Voora D, Cavallari LH, Whirl-Carrillo M, Duarte JD, Luzum JA, Pharmacogenomics Global Research Network (PGRN) Publications Committee. PMID: 37303270; PMCID: PMC10406163.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    7. Gene expression in African Americans, Puerto Ricans and Mexican Americans reveals ancestry-specific patterns of genetic architecture. Nat Genet. 2023 06; 55(6):952-963. Kachuri L, Mak ACY, Hu D, Eng C, Huntsman S, Elhawary JR, Gupta N, Gabriel S, Xiao S, Keys KL, Oni-Orisan A, Rodríguez-Santana JR, LeNoir MA, Borrell LN, Zaitlen NA, Williams LK, Gignoux CR, Burchard EG, Ziv E. PMID: 37231098; PMCID: PMC10260401.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCells
    8. Development and application of an algorithm for statin-induced myopathy based on electronic health record-derived structured elements. medRxiv. 2023 Apr 25. Oni-Orisan A, Lu M, Peng JA, Krauss RM, Iribarren C, Medina MW. PMID: 37162948; PMCID: PMC10168492.
      View in: PubMed   Mentions:
    9. Advancing CYP2D6 Pharmacogenetics through a Pharmacoequity Lens. Clin Pharmacol Ther. 2023 07; 114(1):69-76. Kehinde O, Ramsey LB, Gaedigk A, Oni-Orisan A. PMID: 36924260.
      View in: PubMed   Mentions: 3     Fields:    
    10. Diversity in Clinical Pharmacology: A Call to Action. Clin Pharmacol Ther. 2023 03; 113(3):483-485. Brown K, Etrouth S, Jayachandran P, Moore J, Oni-Orisan A, Vasist L, Zheng S, Zhou Z, Dresser M. PMID: 36710622; PMCID: PMC10024964.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    11. A large genome-wide association study of QT interval length utilizing electronic health records. Genetics. 2022 11 30; 222(4). Hoffmann TJ, Lu M, Oni-Orisan A, Lee C, Risch N, Iribarren C. PMID: 36271874; PMCID: PMC9713425.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    12. Polygenic Risk Score and Statin Relative Risk Reduction for Primary Prevention of Myocardial Infarction in a Real-World Population. Clin Pharmacol Ther. 2022 11; 112(5):1070-1078. Oni-Orisan A, Haldar T, Cayabyab MAS, Ranatunga DK, Hoffmann TJ, Iribarren C, Krauss RM, Risch N. PMID: 35862449; PMCID: PMC10112337.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansPHPublic Health
    13. Modest effect of statins on fasting glucose in a longitudinal electronic health record based cohort. Cardiovasc Diabetol. 2022 07 14; 21(1):132. Haldar T, Oni-Orisan A, Hoffmann TJ, Schaefer C, Iribarren C, Krauss RM, Medina MW, Risch N. PMID: 35836181; PMCID: PMC9284686.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    14. Perceptions of Older Men Using a Mobile Health App to Monitor Lower Urinary Tract Symptoms and Tamsulosin Side Effects: Mixed Methods Study. JMIR Hum Factors. 2021 Dec 24; 8(4):e30767. Wang EY, Breyer BN, Lee AW, Rios N, Oni-Orisan A, Steinman MA, Sim I, Kenfield SA, Bauer SR. PMID: 34951599; PMCID: PMC8742207.
      View in: PubMed   Mentions: 1     Fields:    
    15. Tracking Lower Urinary Tract Symptoms and Tamsulosin Side Effects Among Older Men Using a Mobile App (PERSONAL): Feasibility and Usability Study. JMIR Form Res. 2021 Dec 10; 5(12):e30762. Lee AW, Kenfield SA, Wang EY, Enriquez A, Oni-Orisan A, Steinman MA, Sim I, Breyer BN, Bauer SR. PMID: 34889745; PMCID: PMC8709917.
      View in: PubMed   Mentions: 2  
    16. QT Interval Dynamics and Cardiovascular Outcomes: A Cohort Study in an Integrated Health Care Delivery System. J Am Heart Assoc. 2021 10 05; 10(19):e018513. Mantri N, Lu M, Zaroff JG, Risch N, Hoffmann T, Oni-Orisan A, Lee C, Jorgenson E, Iribarren C. PMID: 34581201; PMCID: PMC8649135.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    17. Torsade de pointes: A nested case-control study in an integrated healthcare delivery system. Ann Noninvasive Electrocardiol. 2022 01; 27(1):e12888. Mantri N, Lu M, Zaroff JG, Risch N, Hoffmann T, Oni-Orisan A, Lee C, Iribarren C. PMID: 34547155; PMCID: PMC8739596.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    18. Advancing Precision Medicine Through the New Pharmacogenomics Global Research Network. Clin Pharmacol Ther. 2021 09; 110(3):559-562. Giacomini KM, Karnes JH, Crews KR, Monte AA, Murphy WA, Oni-Orisan A, Ramsey LB, Yang JJ, Whirl-Carrillo M. PMID: 34318925; PMCID: PMC8881968.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    19. Effect of SLCO1B1 T521C on Statin-Related Myotoxicity With Use of Lovastatin and Atorvastatin. Clin Pharmacol Ther. 2021 09; 110(3):733-740. Lu B, Sun L, Seraydarian M, Hoffmann TJ, Medina MW, Risch N, Iribarren C, Krauss RM, Oni-Orisan A. PMID: 34114646; PMCID: PMC8376784.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    20. Leveraging innovative technology to generate drug response phenotypes for the advancement of biomarker-driven precision dosing. Clin Transl Sci. 2021 05; 14(3):784-790. Oni-Orisan A, Srinivas N, Mehta K, Das JL, Nguyen TT, Tison GH, Bauer SR, Burian M, Funk RS, Graham RA, Biomarkers and Translational Tools Community Working Group of the American Society for Clinical Phar. PMID: 33421282; PMCID: PMC8212753.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    21. Embracing Genetic Diversity to Improve Black Health. N Engl J Med. 2021 Mar 25; 384(12):1163-1167. Oni-Orisan A, Mavura Y, Banda Y, Thornton TA, Sebro R. PMID: 33567186.
      View in: PubMed   Mentions: 48     Fields:    Translation:Humans
    22. PERSONAL: Feasibility Study Protocol for Placebo-Controlled, Randomized n-of-1 Trials of Tamsulosin for Lower Urinary Tract Symptoms. Front Digit Health. 2020; 2:7. Bauer SR, Breyer BN, Oni-Orisan A, Steinman MA, Sim I, McCulloch CE, Kenfield SA. PMID: 34713020; PMCID: PMC8521798.
      View in: PubMed   Mentions: 2  
    23. The impact of adjusting for baseline in pharmacogenomic genome-wide association studies of quantitative change. NPJ Genom Med. 2020; 5:1. Oni-Orisan A, Haldar T, Ranatunga DK, Medina MW, Schaefer C, Krauss RM, Iribarren C, Risch N, Hoffmann TJ. PMID: 31969989; PMCID: PMC6965183.
      View in: PubMed   Mentions: 10  
    24. Assessing the clinical impact of CYP2C9 pharmacogenetic variation on phenytoin prescribing practice and patient response in an integrated health system. Pharmacogenet Genomics. 2019 10; 29(8):192-199. Fohner AE, Ranatunga DK, Thai KK, Lawson BL, Risch N, Oni-Orisan A, Jelalian AT, Rettie AE, Liu VX, Schaefer CA. PMID: 31461080; PMCID: PMC6989102.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    25. Characterization of Statin Low-Density Lipoprotein Cholesterol Dose-Response Using Electronic Health Records in a Large Population-Based Cohort. Circ Genom Precis Med. 2018 09; 11(9):e002043. Oni-Orisan A, Hoffmann TJ, Ranatunga D, Medina MW, Jorgenson E, Schaefer C, Krauss RM, Iribarren C, Risch N. PMID: 30354326; PMCID: PMC6214660.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    26. Association between the EPHX2 p.Lys55Arg polymorphism and prognosis following an acute coronary syndrome. Prostaglandins Other Lipid Mediat. 2018 09; 138:15-22. Oni-Orisan A, Cresci S, Jones PG, Theken KN, Spertus JA, Lee CR. PMID: 30096423; PMCID: PMC6162147.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    27. Projected impact of a multigene pharmacogenetic test to optimize medication prescribing in cardiovascular patients. Pharmacogenomics. 2018 06 01; 19(9):771-782. Dong OM, Li A, Suzuki O, Oni-Orisan A, Gonzalez R, Stouffer GA, Lee CR, Wiltshire T. PMID: 29793377; PMCID: PMC6367721.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    28. Validation of Electronic Health Records for the Assessment of Statin Dosing In Research. Journal of Clinical Lipidology. 2017 May 1; 11(3):836-837. Oni-Orisan OA, Hoffmann HT, Medina MM, Jorgenson JE, Schaefer SC, Krauss KR, Iribarren IC, Risch RN. .
      View in: Publisher Site   Mentions:
    29. Blood pressure-associated polymorphism controls ARHGAP42 expression via serum response factor DNA binding. J Clin Invest. 2017 Feb 01; 127(2):670-680. Bai X, Mangum KD, Dee RA, Stouffer GA, Lee CR, Oni-Orisan A, Patterson C, Schisler JC, Viera AJ, Taylor JM, Mack CP. PMID: 28112683; PMCID: PMC5272192.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansAnimalsCells
    30. Cytochrome P450-derived epoxyeicosatrienoic acids and coronary artery disease in humans: a targeted metabolomics study. J Lipid Res. 2016 Jan; 57(1):109-19. Oni-Orisan A, Edin ML, Lee JA, Wells MA, Christensen ES, Vendrov KC, Lih FB, Tomer KB, Bai X, Taylor JM, Stouffer GA, Zeldin DC, Lee CR. PMID: 26555503; PMCID: PMC4689337.
      View in: PubMed   Mentions: 31     Fields:    Translation:Humans
    31. Pharmacogenomics in heart failure: where are we now and how can we reach clinical application? Cardiol Rev. 2014 Sep-Oct; 22(5):193-8. Oni-Orisan A, Lanfear DE. PMID: 25093738; PMCID: PMC4329642.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    32. Epoxyeicosatrienoic acids and cardioprotection: the road to translation. J Mol Cell Cardiol. 2014 Sep; 74:199-208. Oni-Orisan A, Alsaleh N, Lee CR, Seubert JM. PMID: 24893205; PMCID: PMC4115045.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCells
    33. Acute decompensated heart failure: evolving literature and implications for future practice. Pharmacotherapy. 2014; 34(4):373-88. Cicci JD, Reed BN, McNeely EB, Oni-Orisan A, Patterson JH, Rodgers JE. PMID: 24214219.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    34. Dual modulation of cyclooxygenase and CYP epoxygenase metabolism and acute vascular inflammation in mice. Prostaglandins Other Lipid Mediat. 2013 Jul-Aug; 104-105:67-73. Oni-Orisan A, Deng Y, Schuck RN, Theken KN, Edin ML, Lih FB, Molnar K, DeGraff L, Tomer KB, Zeldin DC, Lee CR. PMID: 23000418; PMCID: PMC3549041.
      View in: PubMed   Mentions: 12     Fields:    Translation:Animals
    35. Enalapril reverses high-fat diet-induced alterations in cytochrome P450-mediated eicosanoid metabolism. Am J Physiol Endocrinol Metab. 2012 Mar 01; 302(5):E500-9. Theken KN, Deng Y, Schuck RN, Oni-Orisan A, Miller TM, Kannon MA, Poloyac SM, Lee CR. PMID: 22185841; PMCID: PMC3311291.
      View in: PubMed   Mentions: 25     Fields:    Translation:Animals
    Akinyemi's Networks
    Concepts (167)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (30)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (59)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).

    We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use. This site is running Profiles RNS version UCSF-v3.1.0-6-g69de2244 on PROFILES-PWEB03.

    Copyright © The Regents of the University of California.